Safety and Efficacy of Fillers for Contouring the Jawline

NCT ID: NCT06336759

Last Updated: 2024-05-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-11-11
• Study Completion Date: 2023-11-10

Brief Summary

The study's goal is to assess the safety and efficacy of two hyaluronic acid products, Restylane Lyft and Defyne, for contouring the jawline and chin, in order to address concerns regarding contour deficiencies among patients seeking aesthetic treatments.

Conditions

Jawline Contour Deficit

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Retylane Defyne

Restylane Defyne is manufactured by Q-Med AB, part of the Galderma Group.

The product is a sterilized 1ml gel syringe contain 20 mg/mL stabilized HA and 3 mg/mL lidocaine hydrochloride in a physiological buffer (phosphate buffered saline pH 7).

The participants deemed to have think skin will be treated at the Baseline visit and will be eligible for retreatment 2 weeks later if a touch up is deemed necessary by the Treating Investigator. Volumes used for each subject will be determined by the aesthetic judgement of the Treating Investigator.

Group Type: ACTIVE_COMPARATOR

Restylane Defyne

Intervention Type: DEVICE

Twenty (20) subjects with thin skin will be recruited and treated with Restylane Defyne.

Retylane Lyft

Restylane Defyne is manufactured by Q-Med AB, part of the Galderma Group.

The product is a sterilized 1mL gel syringe contain 20 mg/mL stabilized HA and 3 mg/mL lidocaine hydrochloride in a physiological buffer (phosphate buffered saline pH 7).

The participants deemed to have thick skin will be treated at the Baseline visit and will be eligible for retreatment 2 weeks later if a touch up is deemed necessary by the Treating Investigator. Volumes used for each subject will be determined by the aesthetic judgement of the Treating Investigator.

Group Type: ACTIVE_COMPARATOR

Restylane Lyft

Intervention Type: DEVICE

Twenty (20) subjects with thick skin will be recruited and treated with Restylane Lyft.

Interventions

Restylane Defyne

Twenty (20) subjects with thin skin will be recruited and treated with Restylane Defyne.

Intervention Type: DEVICE

Restylane Lyft

Twenty (20) subjects with thick skin will be recruited and treated with Restylane Lyft.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. A score > 1 on the Raspaldo Jawline Scale, as assessed by the treating physician at Baseline. A possible secondary deficit of the chin is allowed.

2. Males and females aged > 18 years.

3. Ability to adequately understand the verbal explanations and the written subject information provided in local language and ability and willingness to give consent to participate in the study.

4. Signed and dated informed consent to participate in the study.

5. If female of childbearing potential: a negative urine pregnancy test before all treatments is required.

Exclusion Criteria

1. Current pregnancy or lactation [sexually active women of childbearing age must agree to use medically acceptable methods of contraception for the duration of this study (e.g., oral contraceptives, condoms, intrauterine device, shot/injection, patch)].

2. Subjects presenting with known allergy to hyaluronic acid fillers or amide local anesthetics.

3. Subjects presenting with porphyria.

4. Subjects with active disease, such as inflammation, infection or tumors, in or near the intended treatment sites.

5. Subjects with history of bleeding disorders or subjects taking thrombolytics or anticoagulants.

6. Subjects taking inhibitors of platelet aggregation (e.g., Aspirin or other non-steroid anti-inflammatory drugs [NSAIDs]), within 2 weeks before treatment.

7. Subjects using immunosuppressants.

8. History of permanent implants in the lower face.

9. History of other treatment/procedure that, in the treating investigator's opinion, would interfere with the study injections and/or study assessments or exposes the subject to undue risk by study participation.

10. Visible markings that in the treating investigator's opinion, may interfere with results or assessments.

11. Inability to comply with follow-up and abstain from other treatments in the region of interest during the study period.

12. Heavy smokers, classified as smoking more than 12 cigarettes per day.

13. History of severe or multiple allergies manifested by anaphylaxis.

14. Previous tissue revitalization therapy in the treatment area within 6 months before treatment with laser or light, mesotherapy, radiofrequency, ultrasound, cryotherapy, chemical peeling, or dermabrasion.

15. Previous treatment with neurotoxins in the area under assessment, within 6 months prior to enrolment.

16. Previous treatment with soft tissue fillers in the area under assessment, within 12 months prior to enrolment.

17. Cancer or precancer in the treatment area (e.g., actinic keratosis).

18. Subjects with a tendency to form hypertrophic scars or any other healing disorders.

19. Subjects with a mean skin thickness in the treatment areas between 1.29mm and 1.49mm (ie, "normal" thickness), as determined by ultrasound at Baseline, to ensure no overlap between the two strata (ie, thin and thick skin).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Erevna Innovations Inc.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andreas Nikolis, MD

Role: PRINCIPAL_INVESTIGATOR

Erevna Innovations Inc.

Locations

Erevna Innovations Inc.

Montreal, Quebec, Canada

Countries

Canada

Other Identifiers

2021-10-GAL-JWL

Identifier Type: -

Identifier Source: org_study_id